Real-Time Detection of Infusion Site Failures in a Closed-Loop Artificial Pancreas

Background: As evidence emerges that artificial pancreas systems improve clinical outcomes for patients with type 1 diabetes, the burden of this disease will hopefully begin to be alleviated for many patients and caregivers. However, reliance on automated insulin delivery potentially means patients will be slower to act when devices stop functioning appropriately. One such scenario involves an insulin infusion site failure, where the insulin that is recorded as delivered fails to affect the patient’s glucose as expected. Alerting patients to these events in real time would potentially reduce hyperglycemia and ketosis associated with infusion site failures. Methods: An infusion site failure detection algorithm was deployed in a randomized crossover study with artificial pancreas and sensor-augmented pump arms in an outpatient setting. Each arm lasted two weeks. Nineteen participants wore infusion sets for up to 7 days. Clinicians contacted patients to confirm infusion site failures detected by the algorithm and instructed on set replacement if failure was confirmed. Results: In real time and under zone model predictive control, the infusion site failure detection algorithm achieved a sensitivity of 88.0% (n = 25) while issuing only 0.22 false positives per day, compared with a sensitivity of 73.3% (n = 15) and 0.27 false positives per day in the SAP arm (as indicated by retrospective analysis). No association between intervention strategy and duration of infusion sets was observed (P = .58). Conclusions: As patient burden is reduced by each generation of advanced diabetes technology, fault detection algorithms will help ensure that patients are alerted when they need to manually intervene. Clinical Trial Identifier: www.clinicaltrials.gov,NCT02773875

[1]  Daniel Howsmon,et al.  Closed-Loop Control Without Meal Announcement in Type 1 Diabetes. , 2017, Diabetes technology & therapeutics.

[2]  Eyal Dassau,et al.  Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial , 2017, Diabetes Care.

[3]  Eyal Dassau,et al.  Outpatient Closed-Loop Control with Unannounced Moderate Exercise in Adolescents Using Zone Model Predictive Control. , 2017, Diabetes technology & therapeutics.

[4]  Ulla Linding Jørgensen,et al.  Diabetic Ketoacidosis Among Patients Treated With Continuous Subcutaneous Insulin Infusion , 2017, Journal of diabetes science and technology.

[5]  R. Beck,et al.  Evaluation of Pump Discontinuation and Associated Factors in the T1D Exchange Clinic Registry , 2017, Journal of diabetes science and technology.

[6]  G. Freckmann,et al.  Randomized Cross-Over Study Comparing Two Infusion Sets for CSII in Daily Life , 2017, Journal of diabetes science and technology.

[7]  Benyamin Grosman,et al.  Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes , 2017, Diabetes technology & therapeutics.

[8]  Daniel Howsmon,et al.  Continuous Glucose Monitoring Enables the Detection of Losses in Infusion Set Actuation (LISAs) , 2017, Sensors.

[9]  C. Cobelli,et al.  Insulin Infusion Set Use: European Perspectives and Recommendations , 2016, Diabetes technology & therapeutics.

[10]  Eyal Dassau,et al.  Periodic zone-MPC with asymmetric costs for outpatient-ready safety of an artificial pancreas to treat type 1 diabetes , 2016, Autom..

[11]  Bruce Buckingham,et al.  Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes. , 2016, Diabetes technology & therapeutics.

[12]  R. Hovorka,et al.  Coming of age: the artificial pancreas for type 1 diabetes , 2016, Diabetologia.

[13]  Michael A. Gibney,et al.  Reduced Silent Occlusions with a Novel Catheter Infusion Set (BD FlowSmart): Results from Two Open-Label Comparative Studies , 2016, Diabetes technology & therapeutics.

[14]  T. Bailey,et al.  The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System , 2015, Diabetes technology & therapeutics.

[15]  D. Klonoff,et al.  Using Insulin Infusion Sets in CSII for Longer Than the Recommended Usage Time Leads to a High Risk for Adverse Events , 2015, Journal of diabetes science and technology.

[16]  R. Beck,et al.  Rates of Diabetic Ketoacidosis: International Comparison With 49,859 Pediatric Patients With Type 1 Diabetes From England, Wales, the U.S., Austria, and Germany , 2015, Diabetes Care.

[17]  Lutz Heinemann,et al.  Insulin Pump Risks and Benefits: A Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting, and Research Needs , 2015, Diabetes Care.

[18]  A BuckinghamBruce,et al.  Inpatient Trial of an Artificial Pancreas Based on Multiple Model Probabilistic Predictive Control with Repeated Large Unannounced Meals , 2014 .

[19]  Eyal Dassau,et al.  Clinical evaluation of an automated artificial pancreas using zone-model predictive control and health monitoring system. , 2014, Diabetes technology & therapeutics.

[20]  Eyal Dassau,et al.  Annals of the New York Academy of Sciences the Artificial Pancreas: Current Status and Future Prospects in the Management of Diabetes , 2022 .

[21]  Roman Hovorka,et al.  Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents , 2014, BMJ Open Diabetes Research and Care.

[22]  J. WheelerBenjamin,et al.  Family perceptions of insulin pump adverse events in children and adolescents. , 2014 .

[23]  J Hans DeVries,et al.  Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. , 2014, Diabetes technology & therapeutics.

[24]  Bruce A Buckingham,et al.  Randomized trial of infusion set function: steel versus teflon. , 2014, Diabetes technology & therapeutics.

[25]  Howard C. Zisser,et al.  Feasibility of Outpatient Fully Integrated Closed-Loop Control , 2013, Diabetes Care.

[26]  H. Chase,et al.  Morbidity and mortality of diabetic ketoacidosis with and without insulin pump care. , 2012, Diabetes technology & therapeutics.

[27]  B. Wayne Bequette,et al.  Challenges and recent progress in the development of a closed-loop artificial pancreas , 2012, Annu. Rev. Control..

[28]  F. Lombardo,et al.  Failure of glycated hemoglobin drop after continuous subcutaneous insulin infusion initiation may indicate patients who discontinue: a 4-year follow-up study in children and adolescents with type 1 diabetes , 2012, Acta Diabetologica.

[29]  L. Heinemann,et al.  Insulin Infusion Set: The Achilles Heel of Continuous Subcutaneous Insulin Infusion , 2012, Journal of diabetes science and technology.

[30]  Moshe Phillip,et al.  Factors associated with increased risk of insulin pump discontinuation in pediatric patients with type 1 diabetes , 2011, Pediatric diabetes.

[31]  Günter Niemeyer,et al.  A Closed-Loop Artificial Pancreas Based on Risk Management , 2011, Journal of diabetes science and technology.

[32]  Eyal Dassau,et al.  Zone Model Predictive Control: A Strategy to Minimize Hyper- and Hypoglycemic Events , 2010, Journal of diabetes science and technology.

[33]  Jean E. Stevenson,et al.  Nurses’ experience of using electronic patient records in everyday practice in acute/inpatient ward settings: A literature review , 2010, Health Informatics J..

[34]  Eyal Dassau,et al.  Control to Range for Diabetes: Functionality and Modular Architecture , 2009, Journal of diabetes science and technology.

[35]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[36]  R. Hanås,et al.  A 2‐yr national population study of pediatric ketoacidosis in Sweden: predisposing conditions and insulin pump use , 2009, Pediatric diabetes.

[37]  Daniel Hind,et al.  Ultrasonic locating devices for central venous cannulation: meta-analysis , 2003, BMJ : British Medical Journal.

[38]  J. Leahy,et al.  Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas , 2008 .